Related Experiment Videos
The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis
1Department of Rheumatology, René Descartes University, School of Medicine, Hôpital Cochin, Paris, France.
Insights
Captopril treatment improved thallium 201 myocardial perfusion in patients with systemic sclerosis. This suggests captopril may benefit scleroderma myocardial disease by enhancing coronary microcirculation.
Area of Science:
- Cardiology
- Rheumatology
- Pharmacology
Background:
- Systemic sclerosis frequently involves myocardial perfusion abnormalities, often linked to coronary microcirculation disturbances.
- Assessing interventions for scleroderma myocardial disease is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the long-term efficacy of captopril in improving myocardial perfusion in systemic sclerosis patients.
- To determine if captopril can mitigate perfusion defects in scleroderma-related heart disease.
Main Methods:
- A 1-year study involving 12 normotensive systemic sclerosis patients treated with captopril (75-150 mg/day).
- Thallium 201 myocardial perfusion imaging was used to assess perfusion defects and global scores.
- A control group of 8 systemic sclerosis patients received no captopril for comparison.
Main Results:
- Captopril significantly reduced the number of myocardial perfusion defects (from 6.5 to 4.4, p<0.02).
- Global thallium scores improved significantly after 1 year of captopril treatment (p<0.05).
- No significant changes in perfusion were observed in the control group.
Conclusions:
- Captopril demonstrates a beneficial effect on thallium 201 myocardial perfusion in systemic sclerosis.
- The findings suggest captopril may be a valuable therapeutic option for scleroderma myocardial disease.
- Further research into captopril's impact on coronary microcirculation in systemic sclerosis is warranted.
Abstract:
In systemic sclerosis, abnormalities of myocardial perfusion are common and may be caused by a disturbance of the coronary microcirculation. We evaluated the long-term effect of captopril (75 to 150 mg per day) on thallium 201 myocardial perfusion in 12 normotensive patients with systemic sclerosis. Captopril significantly decreased the mean (+/- SD) number of segments with thallium 201 myocardial perfusion defects (6.5 +/- 1.9 at baseline and 4.4 +/- 2.7 after 1 year of treatment with captopril; p less than 0.02) and increased the mean global thallium score (9.6 +/- 1.7 at baseline and 11.4 +/- 2.1 after captopril; p less than 0.05). In a control group of eight normotensive patients with systemic sclerosis who did not receive captopril, no significant modification in thallium results occurred. Side effects with captopril included hypotension (six patients), taste disturbances (one patient), and skin rash (one patient). These side effects subsided when the dosage was reduced. These findings demonstrate that captopril improves thallium 201 myocardial perfusion in patients with systemic sclerosis and may therefore have a beneficial effect on scleroderma myocardial disease.